Stem Cell Clinic

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

By Induced Pluripotent Stem Cells

NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024.

See the article here:
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

PDS Biotech Leadership to Participate in March Conferences

By Induced Pluripotent Stem Cells

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.

Read more here:
PDS Biotech Leadership to Participate in March Conferences

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

By Induced Pluripotent Stem Cells

CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025.

Continue reading here:
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

By Induced Pluripotent Stem Cells

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.

Read the rest here:
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Glass House Brands to Host Fourth Quarter and Full Year 2024 Conference Call on March 25, 2025

By Induced Pluripotent Stem Cells

LONG BEACH, Calif. and TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 25, 2025, after market close. The Company will host a conference call to discuss the results at 5:00 p.m. Eastern Time.

More here:
Glass House Brands to Host Fourth Quarter and Full Year 2024 Conference Call on March 25, 2025

Cellectar Biosciences to Present at the 37th Annual Roth Conference

By Induced Pluripotent Stem Cells

FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:

Read the original post:
Cellectar Biosciences to Present at the 37th Annual Roth Conference

→←